The study included dose escalation for monotherapy and combination therapy with cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor used in the therapy of metastatic ER-positive and HER2-negative breast cancer [163]. This evidence concerns the gene ERBB2 and breast carcinoma.